{

Roszdravnadzor announced that a Danish diabetes medication will no longer be supplied to Russia. The news highlights a shift in the availability of foreign-origin treatments for people living with type 2 diabetes in the country.

In November 2022, the Danish pharmaceutical company Novo Nordisk informed Roszdravnadzor that effective in 2024 the supply of Rebelsas, known internationally by the active ingredient semaglutide, would be halted. This decision sets the stage for changes in treatment options for patients who rely on this medication.

During the first quarter of 2023, Rebelsas accounted for 9,240 packages entering civil circulation, with ongoing deliveries planned to conclude by the end of the year. The suspension means healthcare providers and patients will need to adjust to the new supply landscape as robust alternatives exist on the domestic market.

Rebelsas, containing semaglutide, was registered for use in Russia in 2021 and is intended for adult patients with type 2 diabetes. Its role in the broader diabetes management framework is being reassessed in light of the company’s decision and the availability of other therapeutic options from Russian manufacturers and approved imports.

Roszdravnadzor notes that the Russian pharmaceutical market already includes analogues to Rebelsas. This suggests that healthcare professionals have access to substitute treatments with comparable efficacy and safety profiles, helping to maintain continuity of care for patients who require daily or weekly glucose regulation therapies.

Earlier communications indicated that Novo Nordisk had halted shipments of another widely used diabetes medicine, Ozempic, to Russia. This broader pattern from the company is steering a reconsideration of how chronic disease therapies are distributed to the domestic market and what alternative options are being prioritized by regulators and clinicians.